Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling

Molecular Biology of the Cell

Volumn 14, Issue 5, 2003, Pages 1941-1952

  Walker, Heather A ^a   Whitelock, John M ^b   Garl, Pamela J ^a   Nemenoff, Raphael A ^a   Stenmark, Kurt R ^a   Weiser Evans, Mary C M ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; ENZYME INHIBITOR; FIBRONECTIN; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE RELATED NONKINASE; LAMININ; MATRIX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PERLECAN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL GROWTH; CELL PROLIFERATION; CELL SHAPE; CELL SPREADING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; GROWTH STIMULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION;

ANIMALS; CELL DIVISION; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MICE; MYOCYTES, SMOOTH MUSCLE; PROTEIN-TYROSINE KINASES; RATS; SIGNAL TRANSDUCTION; UP-REGULATION;

ANIMALIA;

EID: 0038586462     PISSN: 10591524     EISSN: None     Source Type: Journal    
DOI: 10.1091/mbc.E02-08-0508     Document Type: Article

References (51)

1. Aplin, A.E., and Juliano, R.L. (1999). Integrin and cytoskeletal regulation of growth factor signaling to the MAP kinase pathway. J. Cell Sci. 112, 695-706.
2. Arikawa-Hirasawa, E., Watanabe, H., Takami, H., Hassell, J.R., and Yamada, Y. (1999). Perlecan is essential for cartilage and cephalic development. Nat. Genet. 23, 354-358.
3. Assoian, R.K. (1997). Anchorage-dependent cell cycle progression. J. Cell Biol. 136, 1-4.
4. Bingley, J.A., Hayward, I.P., Campbell, J.H., and Campbell, G.R. (1998). Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J. Vasc. Surg. 28, 308-318.
5. Campbell, J.H., Rennick, R.E., Kalevitch, S.G., and Campbell, G.R. (1992). Heparan sulfate-degrading enzymes induce modulation of smooth muscle phenotype. Exp. Cell. Res. 200, 156-167.
6. FAK, paxillin, and talin. J. Cell Biol. 147, 619-629.
7. Castellot, J.J., Addordzio, M.L., Rosenberg, R.D., and Karnovsky, M.J. (1981). Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J. Cell. Biol. 90, 372-379.
8. Clark, E.A., and Brugge, J.S. (1995). Integrins and signal transduction pathways: the road taken. Science 268, 233-239.
9. Clement, B., Bartolome, S.R., Hassell, J.R., Martin, G.R., and Yamada, Y. (1989). Identification of a cell surface-binding protein for the core protein of basement membrane proteoglycan. J. Biol. Chem. 264, 12467-12471.
10. Clowes, A.W., and Karnovsky, M.J. (1977). Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265, 625-626.
11. Clowes, A.W., Reidy, M.A., and Clowes, M.M. (1983). Mechanisms of stenosis after arterial injury. Lab. Invest. 49, 208-215.
12. Condic, M.L., Snow, D.M., and Letoumeau, P.C. (1999). Embryonic neurons adapt to the inhibitory proteoglycan aggrecan by increasing integrin expression. J. Neurosci. 19, 10036-10043.
13. Cook, C.L., Weiser, M.C.M., Schwartz, P.E., Jones, C.L., and Majack, R.A. (1994). Developmentally timed expression of an embryonic growth phenotype in vascular smooth muscle cells. Circ. Res. 74, 189-196.
14. Costell, M., Carmona, R., Gustafsson, E., Gonzalez-Iriarte, M., Fassler, R., and Munoz-Chapuli, R. (2002). Hyperplastic conotruncal endocardial cushions and transposition of great arteries in perlecan-null mice. Circ. Res. 91, 158-64.
15. Couchman, J.R. (1987). Heterogenous distribution of a basement membrane heparan sulfate proteoglycan in rat tissues. J. Cell. Biol. 105, 1901-1916.
16. Fritze, L.M., Reilly, C.F., and Rosenberg, R.D. (1985). An antiproliferative heparan sulfate species produced by postconfluent smooth muscle cells. J. Cell. Biol. 100, 1041-1049.
17. Giancotti, F.G., and Ruoslahti, E. (1999). Integrin signaling. Science 285, 1028-1032.
18. Gilmore, A.P., and Romer, L.H. (1996). Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol. Biol. Cell 7, 1209-1224.
19. Hassell, J.R., Robey, P.G., Barrach, H.J., Wilczek, J., Rennard, S.I., and Martin, G.R. (1980). Isolation of a heparan sulfate-containing proteoglycan from basement membrane. Proc. Natl. Acad. Sci. USA 77, 4494-4498.
20. Hedin, U., Bottger, B.A., Forsberg, E., Johansson, S., and Thyberg, J. (1988). Diverse effects of fibronectin and laminin on phenotypic modulation of cultured arterial smooth muscle cells. J. Cell Biol. 107, 307-319.
21. Hedin, U., Roy, J., Tran, P.K., Lundmark, K., and Rahman, A. (1999). Control of smooth muscle cell proliferation: the role of the basement membrane. Thromb. Hemost. 82(S1), 23-26.
22. Heickendorff, L. (1989). The basement membrane of arterial smooth muscle cells. APMIS S9, 97:1-32.
23. Howe, A., Aplin, A.E., Alahari, S.K., and Juliano, R.L. (1998). Integrin signaling and cell growth control. Curr. Opin. Cell Biol. 10, 220-231.
24. Iozzo, R.V., Cohen, I.R., Grassel, S., and Murdoch, A.D. (1994). The biology of perlecan: the multifaceted heparan sulfate proteoglycan of basement membranes and pericellular matrices. Biochem. J. 302, 625-639.
25. Jones, P.L., Crack, J., and Rabinovitch, M. (1997). Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J. Cell. Biol. 139, 279-293.
26. Kleinman, H.K., McGarvey, M.L., Hassell, M.L., Jr., Star, V.L., Cannon, F.B., Laurie, G.W., and Martin, G.R. (1986). Basement membrane complexes with biological activity. Biochemistry 25, 312-318.
27. Li, H., Leung, T.C., Hoffman, S., Balsamo, J., and Lilien, J. (2000). Coordinate regulation of cadherin and integrin function by the chondroitin sulfate proteoglycan neurocan. J. Cell. Biol. 149, 1275-1288.
28. Li, X., Tsai, P., Weider, E.D., Kribben, A., VanPutten, V., Schrier, R.W., and Nemenoff, R.A. (1994). Vascular smooth muscle cells grown on Matrigel: a model of the contractile phenotype with decreased activation of mitogen-activated protein kinase. J. Biol. Chem. 269, 19653-19658.
29. Lindner, V., Majack, R.A., and Reidy, M.A. (1990). Basic fibroblast growth factor stimulates endothelial regrowth in denuded arteries in vivo. J. Clin. Invest. 85, 2004-2008.
30. Lundmark, K., Tran, P.K., Kinsella, M.G., Clowes, A.W., Wight, T.N., and Hedin, U. (2001). Perlecan inhibits smooth muscle cell adhesion to fibronectin: role of heparan sulfate. J. Cell. Physiol. 188, 67-74.
31. Mercedes, C., Gustafsson, E., Aszodi, A., Morgelin, M., Bloch, W., Hunziker, E., Addicks, K., Timpl, R., and Fassler, R. (1999). Perlecan maintains the integrity of cartilage and some basement membranes. J. Cell. Biol. 147, 1109-1122.
32. Motamed, K., Funk, S.E., Koyama, H., Ross, R., Raines, E.W., and Sage, E.H. (2002). Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. J. Cell. Biochem. 84, 759-771.
33. Murdoch, A.D., Liu, B., Schwarting, R., Tuan, R.S., and Iozzo, R.V. (1994). Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain IlI and by in situ hybridization. J. Histochem. Cytochem. 42, 239-249.
34. Nolan, K.J., Lacoste, J., and Parsons, J.T. (1999). Regulated expression of focal adhesion kinase-related nonkinase, the autonomously expressed c-terminal domain of focal adhesion kinase. Mol. Cell. Biol. 19, 6120-6129.
35. Nordeen, S.K. (1988). Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechrniques 6, 454-458.
36. Nugent, M.A., Nugent, H.M., Iozzo, R.V., Sanchack, K., and Edelman, E.R. (2000). Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhition of intimal hyperplasia. Proc. Natl. Acad. Sci. USA 97, 6722-6727.
37. Paka, L., Goldberg, I.J., Obunike, J.C., Choi, S., Saxena, U., Goldberg, I.D., and Pillarisetti, S. (1999). Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. J. Biol. Chem. 274, 1-6.
38. Renshaw, M.W., Price, L.S., and Schwartz, M.A. (1999). Focal adhesion kinase mediates the integrin signaling requirement for growth factor activation of MAP kinase. J. Cell. Biol. 147, 611-618.
39. Richardson, A., and Parsons, J.T. (1996). A mechanism for regulation of the adhesion-associated protein tyrosine kinase pp125FAK. Nature 380, 538-540.
40. Schaller, M.D., and Parsons, J.T. (1994). Focal adhesion kinase and associated proteins. Curr. Opin. Cell Biol. 6, 705-710.
41. Sieg, D.J., Hauck, C.R., Ilic, D., Klingbeil, C.K., Schaefer, E., Damsky, C.H., and Schlaepfer, D.D. (2000). FAK integrates growth factor and integrin signals to promote cell migration. Nat. Cell Biol. 275, 14729-14735.
42. Tamura, M., Gu, J., Damen, E.H., Takino, T., Miyamoto, S., and Yamada, K.M. (1999). PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol-3-kinase/Akt cell survival pathway. J. Biol. Chem. 274, 20693-20703.
43. Taylor, J.M., Mack, C.P., Nolan, K., Regan, C.P., Owens, G.K., and Parsons, J.T. (2001). Selective expression of an endogenous inhibitor of FAK regulates proliferation and migration of vascular smooth muscle cells. Mol. Cell. Biol. 21, 1565-1572.
44. Thyberg, J., and Hultgardh-Nilsson, A. (1994). Fibronectin and the basement membrane components laminin and collagen type IV influence the phenotypic properties of subcultured rat aortic smooth muscle cell differently. Cell Tissue Res. 276, 263-271.
45. Weiser, M.C.M., Belknap, J.K., Grieshaber, S.S., Kinsella, M.G., and Majack, R.A. (1996). Developmental regulation of perlecan gene expression in aortic smooth muscle cells. Matrix Biol. 15, 331-340.
46. Weiser, M.C.M., Majack, R.A., Tucker, A., and Orton, E.C. (1995). Static tension is associated with increased smooth muscle cell DNA synthesis in rat pulmonary arteries. Am. J. Physiol. 268, H1133-H1138.
47. Weiser, M.C.M., Schwartz, P.E., Grieshaber, N.A., and Majack, R.A. (1997). Perlecan regulates Oct-1 gene expression in vascular smooth muscle cells. Mol. Biol. Cell 8, 999-1011.
48. Weiser-Evans, M.C.M., Quinn, B.E., Burkard, M.R., and Stenmark, K.R. (2000). Transient reexpression of an embryonic autonomous growth phenotype by adult carotid artery SMC following vascular injury. J. Cell. Physiol. 182, 12-23.
49. Weiser-Evans, M.C.M., and Stenmark, K.R. (1999). Perlecan heparan sulfates in the control of vascular smooth muscle cell proliferation. In: The Fetal and Neonatal Pulmonary Circulation, eds. E.K. Weir, S.L. Archer, and J.T. Reeves, Armonk, NY: Futura.
50. Whitelock, J.M. (2000). Purification of perlecan from endothelial cells, In Methods in Molecular Biology, Vol. 171, Proteoglycan Protocols, ed. R.V. Iozzo, Totowa, NJ: Humana Press.
51. Whitelock, J.M., Graham, L.D., Melrose, J., Murdoch, A.D., Iozzo, R.V., and Underwood, P.A. (1999). Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol. 18, 163-178.